General Information of Drug Combination (ID: DCXTN17)

Drug Combination Name
Hepzato TEM
Indication
Disease Entry Status REF
Astrocytoma Investigative [1]
Component Drugs Hepzato   DM2AZPP TEM   DMLNFWU
N.A. Small molecular drug
High-throughput Screening Result Testing Cell Line: U251
Zero Interaction Potency (ZIP) Score: 5.27
Bliss Independence Score: 7.72
Loewe Additivity Score: 3.77
LHighest Single Agent (HSA) Score: 2.42

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Astrocytoma DC2TA3A SNB-19 Investigative [1]
Glioma DCN17TL SF-295 Investigative [1]
Invasive ductal carcinoma DCZ1CSG T-47D Investigative [4]
Invasive ductal carcinoma DCCBBXH HS 578T Investigative [4]
Adenocarcinoma DCF77QR SW-620 Investigative [5]
Amelanotic melanoma DC3DB6L MDA-MB-435 Investigative [5]
Amelanotic melanoma DCGVE6T M14 Investigative [5]
------------------------------------------------------------------------------------
⏷ Show the Full List of 7 DrugCom(s)

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 ClinicalTrials.gov (NCT05022901) An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma. U.S.National Institutes of Health.
3 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030055)
4 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.
5 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.